Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
1. Stryker's Q4 earnings beat estimates at $4.01 per share. 2. Sales reached $6.44 billion, exceeding expectations by 10.7%. 3. Analysts raised price targets, indicating strong growth potential. 4. CFO Glenn Boehnlein announced retirement; the Spine Implant business is being sold. 5. 2025 guidance suggests continued organic growth, margins, and EPS improvement.